Phase III study of S-1 plus intravenous and introperitoneal paclitaxel for pancreatic ductal adenocarcinoma patients with peritoneal metastasis - Phase III study for pancreatic ductal adenocarcinoma patients with peritoneal metastasis

Study group of pancreatic cancer with peritoneal metastasis0 个研究点目标入组 180 人开始时间: 2017年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Metastasis to distant organ sites such as the liver, lungs, bone and so on except ovary 2.resectable pancreatic ductal adenocarcinoma defined by NCCN guideline with positive peritoneal washing cytology 3.contraindication of S-1 gemcitabine, nab-paclitaxel, and paclitaxel 4. evident infection or inflammation on the entry of the study 5.severe herat disease 6.severe co-morbid diseases 7.highly amount of ascites 8.active intestinal bleeding 9.diarrhea (4 time or more in a day) 10. psychiatric disease 11. other active concomitant malignancies 12. pregnat (probable) or feeding women 13. a patient recognized as inappropriate 14. a petient receiving flucytosine, fenitoin, or warfarin. 15. a patient with allergic reaction to S-1, gemcitabine, nab-paclitaxel and paclitaxel 16. a patient with direct tumor invation to the intestine diagnosed by endoscopy or CT scan 17. a patient who cannot give appropriate informed consent other severe medical conditions; contraindication of Gemcitabine, nabpaclitaxel or Paclitaxel, or Pregnant woman

发起方

Study group of pancreatic cancer with peritoneal metastasis